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Abstract 48 
 Diabetes mellitus is a common endocrinopathy in humans and in cats. The 49 
general prevalence of diabetes mellitus, and in particular of type 2 diabetes, has risen 50 
dramatically in recent years. This increase has often been linked to the rise in the 51 
obesity pandemic because obesity and the ensuing metabolic consequences constitute 52 
major risk factors for human type 2 and for feline diabetes. Feline diabetes shares many 53 
features of human type 2 diabetes in respect to its pathophysiology, underlying risk 54 
factors and treatment strategies. This review will briefly summarize major characteristics 55 
in the human and the feline disease and where available, point out the current 56 
knowledge on similarities and differences. 57 
Human Type 2 Diabetes mellitus 58 
Human type 2 diabetes (T2DM) is a metabolic disorder which arises from 59 
the relative inability of the endocrine pancreas to meet increasing metabolic 60 
demands and to compensate for insulin resistance. Insulin resistance is a state of 61 
reduced responsiveness of insulin-target tissues to normal circulating levels of 62 
insulin. The degree to which glucose tolerance deteriorates in insulin-resistant 63 
individuals varies as a function of both the magnitude of insulin resistance and the 64 
capacity of the pancreas to adequately compensate for this defect. If insulin 65 
secretion fails to fully compensate, a condition of hyperglycemia despite 66 
hyperinsulinemia occurs. Hence, the worsening of insulin resistance together with 67 
abnormalities in compensatory insulin secretion and finally a failure of beta-cell 68 
function may eventually lead to the development of T2DM [58]. 69 
1 Epidemiology 70 
1.1 Genetics 71 
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 T2DM is a multifactorial disease influenced by heterogeneous factors including 72 
diet, physical activity, age and genes. Genetic predisposition is a key contributing factor 73 
in T2DM; the expression of a number of gene variants, including some genes encoding 74 
for transcription factors, enzymes involved in glucose metabolism proteins and 75 
molecules of the insulin signalling pathways, has been associated with islet cell 76 
dysfunction. However, none of the known genetic factors alone seems to be responsible 77 
for the vast majority of T2DM patients, despite the high overall heritability of T2DM [9]. 78 
1.2 Glucotoxicity and lipotoxicity 79 
 Among the several acquired factors that impair β-cell function, the role of glucose 80 
toxicity and lipotoxicity is of particular importance. The mechanism of β-cell loss is 81 
attributed to an increase in β-cell apoptosis that is not compensated by adequate 82 
regeneration. Chronic exposure to hyperglycemia has been shown to cause β-cell 83 
hypertrophy and eventually apoptosis; prolonged exposure of human and rodent β-cells 84 
to high glucose levels leads to increased production and release of interleukin-1β (IL-1β) 85 
followed by β-cell specific up-regulation of the rate of apoptosis [36, 38].  86 
 Although fluctuations in free fatty acids (FFAs) levels are critical for normal insulin 87 
release, a prolonged increase in FFAs concentrations (lipotoxicity) is associated with 88 
impairments in insulin biosynthesis and glucose-stimulated insulin secretion. High levels 89 
of saturated FFAs, in particular palmitate, induce apoptosis independently from glucose 90 
in cultured human and rat islets [35, 37]. 91 
1.3. Amyloid deposition 92 
 Concurrent with the effects of hyperglycemia and hyperinsulinemia, abnormalities 93 
in amylin secretion, and in particular abnormalities in the processing of amylin and its 94 
local deposition as amyloid in the islets, may contribute to the progressive loss of β-cell 95 
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in T2DM. In humans, monkeys and cats, but not in mice or rats (which do not 96 
spontaneously develop a T2DM like syndrome), amylin has an amyloidogenic-promoting 97 
region, which resides within amino acids 20 to 29 of the 37 amino acid peptide hormone, 98 
and which predisposes amylin to aggregate and form pancreatic islet amyloid in the 99 
species named above. Islet amyloidogenesis involves the stepwise aggregation of 100 
monomers of amylin into oligomers, fibrils and, ultimately, mature amyloid deposits that 101 
can be observed under light microscopy. However, rather than these large amyloid 102 
deposits, the small amylin oligomers, which are formed in the early stages of fibril 103 
aggregation, might be the toxic principle responsible for amylin-mediated β-cell 104 
cytotoxicity and death. In fact, the toxicity of amylin oligomers seems to derive from the 105 
disruption and leakage of β-cell membranes due to the formation of ion channels/pore 106 
into the membrane [27, 44]. Further, the subsequent growth of amylin fibrils in the 107 
extracellular space impairs nutrients and oxygen uptake into the β-cell which in turn 108 
contributes to endoplasmic reticulum (ER) stress, and ultimately apoptosis [28]. 109 
2 Inflammation and diabetes 110 
 More recently, it has been proposed that inflammation might be the possible 111 
common mechanism embracing the effects of glucotoxicity, lipotoxicity and increased 112 
amyloid deposition on β-cell dysfunction in T2DM. This is suggested by the 113 
pathologically elevated levels of islet-derived cytokines, e.g. IL-1β, and the subsequent 114 
chemokines-mediated recruitment of macrophages observed in diabetic patients [11, 115 
40]. 116 
The first evidence of a possible involvement of inflammation in diabetes can be traced 117 
back to more than a century ago [12] [62], however, it was only in 1993 that the 118 
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pioneering work by Hotamisligil and colleagues [23] causally linked inflammation to the 119 
pathogenesis of obesity, insulin resistance and T2DM. The revolutionary idea that 120 
adipose tissue-derived pro-inflammatory cytokines (e.g. tumor necrosis factor-α [TNF-α]) 121 
are overproduced by fat tissue of obese individuals and that these cytokines are able to 122 
induce insulin resistance in obese subjects, stimulated extensive research regarding the 123 
role of inflammation in the pathogenesis of insulin resistance, obesity and T2DM. 124 
2.1 Inflammation and insulin resistance 125 
 Originally considered to be a passive lipid storage site, adipose tissue is now 126 
known to produce and secrete many signaling proteins that modulate many metabolic 127 
processes. These secretory products, known as “adipokines” or “adipocytokines, either 128 
directly or indirectly control triglyceride (TG) accumulation and differentiation of pre-129 
adipocytes and initiate inflammatory responses in adipose tissue.  130 
2.1.1 Adipokines 131 
 Primary adipokines (such as leptin and adiponectin) are produced primarily or 132 
exclusively by adipocytes.  133 
The plasma leptin concentration correlates with body fat mass and increases and 134 
decreases in response to weight gain or weight loss, respectively, but leptin increases 135 
also more acutely in response to food intake [16]. Leptin stimulates β-oxidation of FA 136 
and inhibits lipogenesis in peripheral tissues; hence leptin functions to decrease TG 137 
content in these tissues and to decrease FA levels in the circulation.  138 
In obesity, the physiological responses to leptin are diminished in the hypothalamus and 139 
possibly elsewhere, and leptin-target cells become resistant to its actions. The 140 
resistance to leptin’s effects in the hypothalamus and the concurrent lowering of the 141 
body's energy metabolism may lead to further weight gain in obese subjects. Resistance 142 
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to leptin action is often associated with severe insulin resistance as the result of 143 
increased ectopic fat accumulation and lipotoxic effects in insulin-sensitive tissues. 144 
 Adiponectin is produced exclusively by mature adipocytes and circulates in 145 
plasma in multimeric form, with the high molecular weight form being the most 146 
biologically active. Its secretion is stimulated by insulin and by dietary constituents such 147 
as amino acids. Adiponectin levels inversely correlate with fat mass, hepatic lipid 148 
content, dyslipidemia and insulin resistance. Adiponectin increases insulin sensitivity 149 
and influences glucose metabolism by increasing glycolysis and FA oxidation. Plasma 150 
levels of adiponectin are lower in subjects with obesity, T2DM, cardiovascular disease, 151 
hypertension, and metabolic syndrome compared to healthy patients. 152 
2.1.2 Adipocytokines 153 
 Among the numerous chemoattractant cytokines secreted by hypertrophied 154 
adipocytes in obesity, monocyte chemotactic protein-1 (MCP-1) has the role to attract 155 
circulating monocytes to migrate into adipose tissue. These recruited monocytes mature 156 
into classically activated macrophages; by secreting TNFα and other cytokines such as 157 
IL-1β, they continue to attract more macrophages.  158 
 TNF-α and IL-6 plasma levels are elevated in obese humans and animals, and 159 
their production in visceral fat seems to be higher than in subcutaneous adipose tissue; 160 
this in principle is consistent with the more deleterious effect of visceral compared to 161 
subcutaneous fat accumulation. Both cytokines inhibit insulin action in adipocytes in part 162 
through serine phosphorylation of insulin receptor substrate (IRS) proteins which lowers 163 
their activity with the subsequent inhibition of insulin-stimulated glucose transport via 164 
GLUT4. In addition, the activation of inflammatory pathways contributes to induce and 165 
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propagate ER stress with detrimental consequences on insulin sensitivity and systemic 166 
metabolism [8]. 167 
2.1.3 Inflammatory lipid mediators 168 
 During prolonged caloric overload, the inappropriate accumulation of lipids in 169 
tissues other than fat, such as liver, skeletal muscle, heart and pancreatic β-cells, which 170 
rarely occurs under physiological conditions, overwhelms the capacity of the cells to 171 
oxidize fat and negatively affects the normal metabolic response and the functional 172 
integrity of the ER. By binding to Toll-like receptor-4 (TLR4) on adipose cells and 173 
macrophages, FFAs can directly drive the activation of the inflammatory signaling 174 
cascade via c-jun-NH2-terminal kinase (JNK) and NF-κβ-Iκβ kinase (IKKβ), which is 175 
directly linked to serine phosphorylation of IRS-1 and IRS-2 and to the impairment of 176 
insulin sensitivity and glucose transport [56]. Therefore, the “sensing” of saturated FFAs 177 
by TLR4 causes a classical activation of inflammatory pathways and contributes to the 178 
development of insulin resistance, suggesting a coupling between inflammation and 179 
insulin resistance, in the setting of obesity. 180 
2.2 Inflammation and pancreatic β-cell function 181 
 During infections and immunologic responses as well as during the metabolic 182 
syndrome, chronic metabolic stress may be responsible for the induction of a deleterious 183 
autoinflammatory process in pancreatic islets that eventually leads to a failure of insulin 184 
secretion and to T2DM. Recent findings suggest that the autoinflammation driven by 185 
increasing levels of glucose, FFA and IL-1β plays a causal role in the pathogenesis of 186 
T2DM [11]. In inflammatory states and in obesity, IL1β synthesis by resident 187 
macrophages in adipose tissue is increased. IL1β, leptin and FFA act directly on the β-188 
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cells in pancreatic islets, inducing further transcription, translation and local release of 189 
IL1β. One of the master effects of IL1β is to induce the production of cytokines and 190 
chemokines from epithelial, endothelial and immunocompetent cells and therefore helps 191 
to increase the recruitment of macrophages into the islets. As a result, infiltrating 192 
macrophages enhance local IL1β production which, in a paracrine fashion, contributes 193 
to the induction of an autoinflammatory circuit in the β-cell inflammation. Increased local 194 
inflammatory responses cause β-cell failure and morphological destruction of the 195 
endocrine pancreas [10]. 196 
Feline diabetes mellitus 197 
 Feline diabetes mellitus (FDM) closely resembles human T2DM in many features. 198 
The prevalence of diabetes in cats has increased enormously in the past years. In the 199 
United Kingdom, it has been suggested that nearly 1 in 200 cats is diabetic, and it has 200 
been estimated there are approximately 1 million diabetic cats in the United States. The 201 
development of complications in several organ systems including peripheral 202 
polyneuropathy and retinopathy, and the (relative) age of disease onset are also 203 
comparable to T2DM [30]. 204 
The typical diabetic cat is middle aged, usually older than 6 years of age, neutered, male 205 
and very often obese. Similar to human T2DM, environmental risk factors, such as 206 
physical inactivity and obesity, play the central role in the development and the 207 
increasing incidence of FDM. Polyuria, polydipsia, polyphagia, muscle wasting and 208 
weight loss are the most common clinical findings of FDM.  209 
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In diabetic cats the first phase of postprandial insulin release has been demonstrated to 210 
be delayed or absent; the second phase secretion usually is also delayed and 211 
sometimes exaggerated. 212 
Despite the similar pathophysiology to human T2DM, insulin therapy is currently the 213 
most effective treatment to achieve glycemic control and to avoid life-threatening 214 
complications in diabetic cats. The reason why other treatment strategies such as oral 215 
antidiabetic drugs seem to be relatively less successful compared to humans may 216 
perhaps relate to the fact that FDM is often diagnosed at a later disease state than 217 
human T2DM. 218 
3 Epidemiology 219 
3.1 Genetics 220 
 A breed predisposition seems to support the idea of a genetic component in the 221 
pathogenesis of FDM. In Burmese cats, one in 50 develops the disease whereas in 222 
domestic cats the frequency of FDM is only one in 200. The predisposition in Burmese 223 
cats is not sex linked or dominant [17]. 224 
3.2 Obesity 225 
 Obesity in cats is generally defined as a 30% excess of body weight above 226 
normal; overweight animals are 10% to 15% above normal. In practice and in a clinical 227 
setting, it is often preferable to use a body condition score (BCS) system to classify body 228 
condition, overweight and obesity in cats. The prevalence of overweight cats, evaluated 229 
with BCS systems, is estimated to vary between 6% and 52% [7, 54, 55].  230 
Like in humans, obesity in cats has been linked to detrimental effects on the health and 231 
longevity. It predisposes cats to the development of a multitude of diseases including 232 
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insulin resistance and feline diabetes, but also hepatic lipidosis, cardiorespiratory 233 
disease and others [68]. 234 
3.3 Neutering 235 
 Neutering has been shown to induce changes in basal metabolism and to be one 236 
of the major risk factors for feline obesity. Both male and female cats increase their food 237 
intake and body fat mass following neutering. Alterations in sex hormones seem to 238 
influence brain centers important for the control of food intake and metabolic rate and 239 
may result in increased energy intake and an overall positive energy balance [25, 39]. It 240 
has been demonstrated that gonadectomy removes the estrogenic inhibition of eating in 241 
female rodents and that these changes are reversed by estradiol treatment [14]. In 242 
principle, consistent with these reports, daily administration of estradiol prevents the 243 
increase in food intake following gonadectomy in both male and female overweight cats 244 
[6]. 245 
4 Pathogenesis of FDM 246 
4.1 Insulin resistance 247 
 Inflammatory conditions may be an independent risk factor for insulin resistance 248 
and diabetes in cats but the causal implications have not yet been studied in detail. It 249 
has been reported that Burmese cats with chronic or recurring periodontal disease have 250 
impaired glycemic control and are more prone to develop diabetes [53].  251 
In obese cats, insulin sensitivity is typically decreased by more than 50% compared to 252 
healthy lean animals [1] [19]; on average, diabetic cats have been found to be about six 253 
times less sensitive to insulin than healthy cats. In fact, each kilogram of weight gain 254 
reduces insulin sensitivity and glucose effectiveness in cats by 30% [20]. Insulin 255 
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resistance in diabetic cats can therefore be reversed by reducing body weight, similar to 256 
what has been observed in obese non-diabetic cats. [3]. Interestingly, obese male cats 257 
have lower innate insulin sensitivity and higher basal insulin concentrations; this may 258 
therefore be one factor explaining why obese male cats are more prone to diabetes than 259 
obese females [1]. 260 
4.2 Glucotoxicity and lipotoxicity  261 
 By using long-term hyperglycemic and hyperlipidemic clamps in cats, it was 262 
possible to study the pathogenesis of β-cell dysfunction and loss induced by excess 263 
glucose or lipids in vivo under well controlled conditions [67]. We showed that severe β-264 
cell dysfunction is rapidly induced by sustained hyperglycemia in cats. Sustained 265 
hyperglycemia strongly impaired β-cell function in cats, and this resulted in β-cell 266 
exhaustion and decreased insulin gene expression [67]. This study supported the 267 
hypothesis that hyperglycemia causes β-cell loss in vivo, as indicated by the 50% 268 
decrease in β-cell count per pancreatic area in glucose-infused cats. This was not 269 
compensated by increased β-cell proliferation. Based on histomorphological features, 270 
hyperglycemic cats had large parts of their islets devoid of nuclei. In most rodent 271 
studies, glucose infusion for 2–4 days either increased or had no effect on β-cell mass 272 
[50, 60], and none of these in vivo experiments demonstrated a demise of β-cells after 273 
infusion. We believe that these differing findings between cats and rodents may be due 274 
to the inherent species difference (e.g. different propensity for amylin to form islet 275 
amyloid which may interact with glucotoxic changes; see below) but other aspects such 276 
as the experimental design of the studies or their duration cannot be excluded at the 277 
time being. 278 
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As to the reason for the reduced number of β-cells in hyperglycemic cats, we found that 279 
apoptotic islet cells and β-cells positive for cleaved caspase-3 were only present in 280 
glucose-infused but not in control cats. Apoptosis may thus contribute to the reduced 281 
number of β-cells in hyperglycemic cats. In the islets isolated from hyperglycemic cats 282 
we found no increase in IL-8 or IL-1β, or the Fas receptor. Hence, in contrast to human 283 
islets exposed to high glucose [34, 38], apoptosis of β-cells in hyperglycemic cats may 284 
have occurred through mechanisms that do not involve local inflammatory reactions or 285 
Fas receptor upregulation.  286 
 In contrast to the detrimental effects of sustained hyperglycemia, hyperlipidemia 287 
leading to increased plasma levels of FFA did not affect basal insulin levels or glucose-288 
stimulated insulin secretion in our experiment [67]. Conflicting results have been 289 
described with regard to the effects of excess free fatty acids on insulin secretion in vivo. 290 
Studies in rats and humans reported increased, decreased or unchanged β-cell function 291 
[15, 49, 59]. Hyperlipidemia and excess FFA levels in cats had no effect on β-cell 292 
number and β-cell apoptosis or proliferation. In cultured human and rat islets, exposure 293 
of β-cells to palmitate was toxic, whereas oleate protected from both palmitic- and 294 
glucose-induced β-cell apopotosis [35]. Some differences between our and other studies 295 
may partly be attributable to the different infusion protocols; in our case, we infused a 296 
lipid solution that was relatively low in saturated long chain fatty acids. 297 
 However, we found that both hyperglycemia and hyperlipidemia induced systemic 298 
inflammation in cats [67]. Hence, systemic inflammation may develop in diabetic cats 299 
similar to what has been described in human T2DM [61]. In contrast to T2DM in humans 300 
[13] and perhaps linked to the relative short duration of infusion, we did not observe an 301 
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inflammatory reaction in islets of hyperglycemic or hyperlipidemic cats, as assessed by 302 
islet transcripts of cytokines or chemokines and by the number of islet neutrophils.  303 
4.3 Amyloid deposition 304 
 More than 80% of diabetic cats seem to have pancreatic amyloid deposition. 305 
Depending on the extent of amyloidosis in diabetic cats, this seems to be associated 306 
with an approximately 50% loss of β-cells mass [33]. β-cell vacuolar degeneration, 307 
chronic pancreatitis and a reduced number of islets or β- cells are other common 308 
histological findings in diabetic cat [47, 52]. However, not all cats with amyloid deposits 309 
develop diabetes [31] and amyloid deposits are also present in non-diabetic cats [32, 310 
63]. In agreement with these findings, we recently observed that the mean amyloid-311 
positive cross-sectional area in the pancreatic samples of 37 diabetic cats did in fact not 312 
differ from sex-, breed- and body weight- matched control cats (unpublished data) [64]; 313 
however, due to the retrospective nature of the study, the causal links could not be 314 
investigated. 315 
4.4 Inflammation and insulin resistance 316 
 As mentioned before, inflammation, particularly in adipose tissue, has been 317 
causally linked to diet- and obesity-related insulin resistance and to the development of 318 
T2DM in several human and rodent studies [21, 22, 57].  319 
4.4.1 Adipokines and adipocytokines 320 
 Similar to humans, secretion of adipokines like leptin and adiponectin from 321 
adipose tissue has been shown in cats [51]. Higher circulating levels of leptin positively 322 
correlate with insulin resistance; it was claimed that this may even occur independent of 323 
changes in body condition score and fat mass [2]. The association between increased 324 
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leptin levels and neutering is most probably related to the increase in fat mass gained 325 
post-neutering [39]. However, a causal inter-relationship between leptin, insulin 326 
resistance and diabetes has not been demonstrated in cats.  327 
 In cats, adiponectin is also produced and secreted exclusively by mature 328 
adipocytes; its gene expression is significantly higher in visceral than other adipose 329 
depots [24, 66]. Recent reports showed that the high molecular weight (HMW) multimers 330 
of adiponectin account for about 80% of total adiponectin in cats while HMW multimers 331 
only account for 30% of total adiponectin in humans [26, 29]. HMW multimers are more 332 
closely associated with insulin sensitivity and body fat mass than total adiponectin [29]. 333 
Plasma adiponectin concentrations negatively correlate with increases in fat mass, and 334 
circulating levels of adiponectin are significantly lower in obese than in normal-weight 335 
cats [20, 24, 46]. Further, it seems that total adiponectin levels are lower in obese 336 
neutered male than in female cats, although this gender difference may not be directly 337 
attributable to sex hormones levels. The role of adiponectin as anti-inflammatory 338 
adipokine has not been investigated in cats.  339 
 Several studies in cats have shown that TNF-α expression in adipose tissue and 340 
in skeletal muscle is increased in obese cats [18, 43]. However, there is a lack of 341 
published data regarding the circulation patterns of adipose-derived TNF-α and other 342 
cytokines in cats, probably due to the unavailability of reliable assays. 343 
 Gene expression of insulin signaling-related genes is decreased in insulin 344 
sensitive tissues of obese cats. To name a few examples, obese cats have decreased 345 
GLUT4 expression in muscle and fat [4], and IRS-2 mRNA levels are lower in skeletal 346 
muscle and liver [45]. 347 
4.4.2 Inflammation and nutrient metabolism 348 
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 In order to study some of the effects of inflammaton on nutrient metabolism in 349 
cats, we recently performed an experiment where subacute inflammation was induced 350 
by 10 days of lipopolysaccharide (LPS) infusion, in the absence of obesity [48]. This 351 
manipulation was sufficient to cause a transient insulin resistance state at the whole-352 
body level, and a long-lasting peripheral and tissue-specific insulin resistance in cats; 353 
both effects were observed in the absence of significant effects on pancreatic β-cell 354 
function. This is in principle agreement with findings in rats and humans, where the 355 
acute administration of LPS has been shown to impair insulin sensitivity but not 356 
pancreatic β-cell function [5].  357 
LPS infusion also lead to an increase of circulating and tissue markers of inflammation in 358 
cats [48]. Further, mRNA and protein analysis revealed that expression of key genes 359 
involved in glucose, lipid and insulin metabolism were altered in a manner consistent 360 
with a tissue-specific reduction in insulin sensitivity. Major changes were observed in 361 
adipose tissue and in particular in the subcutaneous fat depot. This included a reduced 362 
adipocyte size due to increased hormone sensitive lipase activity, decreased high 363 
density lipoprotein cholesterol levels and increased TGs levels in plasma and liver; all 364 
changes pointed to severe dyslipidemia. Among the many results, the observation that 365 
adipocyte size in both fat depots of LPS-infused cats was significantly decreased and 366 
that subcutaneous compared to visceral fat was found to exhibit a much higher 367 
expression of pro-inflammatory factors was particularly noteworthy. In fact, recent 368 
findings showed that in addition to adipose mass and distribution, mean fat cell size is 369 
associated with metabolic complications such as insulin resistance and adipose tissue 370 
inflammation in humans [42]. Further, it has been demonstrated that an increased 371 
proportion of small adipose cells in human subcutaneous adipose tissue is associated 372 
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with inflammation, independently of body mass index and insulin resistance [41]. 373 
Whether such factors play a role in cats is currently unknown. 374 
4.5 Inflammation and β-cell function 375 
 Interestingly, both experimental hyperglycemia and hyperlipidemia induced a 376 
systemic inflammation in cats which resembled that observed in human T2DM [67]. 377 
However, in contrast to the findings in humans, local inflammatory reactions in the islets 378 
were not observed after the hyperglycemic or hyperlipidemic clamps in cats. Hence, 379 
although hyperglycemia (but not hypertriglyceridemia) had detrimental effects on the 380 
endocrine pancreas which resemble those observed in diabetes, these effects did not 381 
seem to depend on the activation of local inflammatory responses, at least during 10-382 
day infusions of glucose or lipids, respectively. We also demonstrated that β-cell 383 
function was impaired during the initial days of endotoxin infusion but that this effect was 384 
no longer detectable by day 10 of the infusion [48]. 385 
 Recently, we assessed whether diabetic cats have pathological evidence of islet 386 
inflammation or pancreatitis and found that the average counts of neutrophils, T- and B-387 
lymphocytes in the islets did not differ between diabetic and healthy cats although the 388 
presence of lymphocytes in general tended to be more frequent in diabetic than control 389 
cats [64]. In addition, a subset of diabetic cats showed lymphocytic infiltration of the 390 
islets that might have contributed to β-cell loss. The results confirmed previous 391 
observations that loss of β-cells occurs in diabetic cats [33] and suggested that 392 
increased necrosis and fibrosis of the exocrine tissue may be associated with 393 
pancreatitis in at least some diabetic cats.  394 
Conclusions 395 
18 
 
 In contrast to current rodent models, cats develop all aspects of the human 396 
disease including obesity-induced insulin resistance, impaired beta cell function, 397 
decreased number of -cells and pancreatic amyloid deposition [1]. Therefore, cats are 398 
considered an interesting and perhaps the best non-primate available model to study the 399 
pathogenesis of human T2DM. Studies using cats may contribute to help developing 400 
preventive strategies and more targeted therapeutic approaches to investigate the 401 
pathogenesis of feline diabetes and, possibly, some of the mechanisms underlying β-402 
cells dysfunction and decreased β-cells mass in T2DM in humans.  403 
 In clinical cases, an adequate control of glycemia in diabetic cats may result in 404 
clinical remission in about 40-80% of cases [65]. Remission likely depends on the 405 
remaining functionality and viability of β-cells in the pancreatic islets and the successful 406 
restoration of normoglycemia by the initial treatment. Because we showed that feline β-407 
cells are very susceptible to the detrimental effects of excess glucose [67], rapid 408 
restoration of normoglycemia and drugs that promote β-cell function or prevent 409 
apoptosis may be tested in cats; such strategies may perhaps prevent β-cell toxicity or 410 
facilitate recovery from the toxic effects of hyperglycemia. In other words, an adequate 411 
control of glycemia may reverse glucose toxicity in the endocrine pancreas and restore 412 
β-cells function and possibly β-cells mass. 413 
 Further, the tissue-specific insulin resistance and severe alterations in lipid 414 
metabolism induced by prolonged LPS infusion suggest that future efforts should 415 
concentrate on the study of the biological processes and the molecular mechanisms that 416 
underlie the tissue-specific development of inflammation and the related metabolic 417 
alterations in cats. 418 
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 Based on the data available to date, it appears that inflammation may not be the 419 
primary mechanism involved in the development of β-cell dysfunction in cats. However, 420 
future studies are needed to clarify whether chronic concurrent infusion of lower doses 421 
of glucose and endotoxin might have a combined effect on β-cells that leads to the 422 
activation of the same inflammatory factors and ultimately mechanisms as in human 423 
T2DM. 424 
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